<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968575</url>
  </required_header>
  <id_info>
    <org_study_id>2019-075-K-74</org_study_id>
    <nct_id>NCT03968575</nct_id>
  </id_info>
  <brief_title>Sub-threshold Micro-Pulse Laser Therapy for Drusen of Dry AMD</brief_title>
  <official_title>The Affiliated Eye Hospital of Wenzhou Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Eye Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Eye Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of sub-threshold micro-pulse laser therapy for drusen
      of dry age-related macular degeneration (AMD) .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in macular drusen volume</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Mean change in macular drusen volume on optical coherence tomograph(OCT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in macular drusen area</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Mean change in macular drusen area on OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Mean change in best-corrected visual acuity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Drusen</condition>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>laser treatment</intervention_name>
    <description>sub-threshold micro-pulse laser treatment</description>
    <arm_group_label>Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Older than 50 years of age.

          2. Male or female patients with nonexudative AMD with a drusen diameter of at least 125um
             in the central 3mm circle

          3. clear media to perform colour, red-free imaging and fundus fluorescein angiography,
             fundus autofluorescence imaging and OCT.

          4. Able to give an informed consent.

        Exclusion Criteria:

          1. Presence of other macular disease such as epiretinal membrane, macular telangiectasia.

          2. unclear media that no clear colour, red-free imaging and fundus fluorescein
             angiography, fundus autofluorescence imaging and OCT can performed.

          3. Ocular or periocular infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Huang</last_name>
    <phone>0577-88068855</phone>
    <email>wzhuangying@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The eye of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Huang</last_name>
      <phone>86-577-88068855</phone>
      <email>wzhuangying@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoling Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Eye Hospital of Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Xiaoling Liu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

